Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
trastuzumab derxutecan · 1 trial · 2 indications
The progression-free survival is the length of time during and after treatment of the disease with T-DXd that a patient lives with the disease but it does not get worse.
| Arm | Type | Description |
|---|---|---|
| T-DXd | EXPERIMENTAL | T-DXd will be administrated as an intra-venous injection of 5.4 mg/kg every three weeks (1 cycle = 21-day treatment). |
| Name | Type | Description |
|---|---|---|
| trastuzumab derxutecan | DRUG | T-DXd will be administrated as an intra-venous injection of 5.4 mg/kg every three weeks (1 cycle = 21-day treatment). |
SCREENING PHASE\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_ Inclusion criteria 1. Patient must have signed the written informed consent for screening phase prior to any trial specific procedures. Note: When the patient is ph...
Top 20 of 84 competitors